Liraglutide is approved for obesity treatment in children starting at what age?

Liraglutide, a GLP-1 receptor agonist, is specifically approved for the treatment of obesity in children starting at the age of 12 years. This approval is based on the results of clinical trials that demonstrated its efficacy and safety when used for weight management in this population. The age restriction is in place to ensure that the medication is used in appropriate candidates and that the benefits outweigh any potential risks, considering the unique physiological and developmental factors involved in treating obesity in younger populations.

In clinical practice, it's essential to consider the full range of available treatments and recommendations for children with obesity, as well as the impressions from clinical trials. However, liraglutide is recognized for its benefits in adolescents aged 12 and older, providing healthcare providers with a valuable treatment option for managing obesity in this demographic.